REMUS

Remus Pharmaceuticals Share Price

₹930.70 +52.15 (5.94%)

13 Jul, 2025 04:41

SIP TrendupStart SIP in REMUS

Start SIP

Performance

  • Low
  • ₹871
  • High
  • ₹934
  • 52 Week Low
  • ₹870
  • 52 Week High
  • ₹1,417
  • Open Price₹874
  • Previous Close₹879
  • Volume8,600

Investment Returns

  • Over 1 Month -3.42%
  • Over 3 Month -8.91%
  • Over 6 Month -19.63%
  • Over 1 Year -8.34%
SIP Lightning

Smart Investing Starts Here Start SIP with Remus Pharmaceuticals for Steady Growth!

Invest Now

Remus Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 37.7
  • PEG Ratio
  • -
  • Market Cap Cr
  • 1,097
  • P/B Ratio
  • 4.3
  • Average True Range
  • 41.79
  • EPS
  • 24.67
  • Dividend Yield
  • 0.1
  • MACD Signal
  • -14.32
  • RSI
  • 47.32
  • MFI
  • 57.28

Remus Pharmaceuticals Financials

Remus Pharmaceuticals Technicals

EMA & SMA

Current Price
₹930.70
+ 52.15 (5.94%)
pointer
  • stock-down_img
  • Bearish Moving Average 12
  • stock-up_img
  • Bullish Moving Average 4
  • 20 Day
  • ₹938.79
  • 50 Day
  • ₹966.90
  • 100 Day
  • ₹1,003.44
  • 200 Day
  • ₹1,029.01

Resistance and Support

911.9 Pivot Speed
  • R3 1,015.80
  • R2 974.90
  • R1 952.80
  • S1 889.80
  • S2 848.90
  • S3 826.80

What's your outlook on Remus Pharmaceuticals?

You can only vote once!

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Remus Pharmaceuticals Ltd. manufactures and markets pharmaceutical formulations, including injectables, tablets, and capsules. The company serves both domestic and international markets, offering high-quality medicines across various therapeutic areas with a focus on affordability and innovation.

Remus Pharmaceuticals Ltd has an operating revenue of Rs. 861.90 Cr. on a trailing 12-month basis. An annual revenue growth of 187% is outstanding, Pre-tax margin of 8% is okay, ROE of 11% is good. The company has a reasonable debt to equity of 1%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 97 which is a GREAT score indicating consistency in earnings, a RS Rating of 14 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D+ which indicates heavy supply, Group Rank of 12 indicates it belongs to a strong industry group of Medical-Whlsle Drg/Suppl and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Remus Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-05-17 Audited Results, Dividend & Others To consider 1. Bonus 2. Other business matters. Interim Dividend of Rs. 2 per equity share.
2024-11-09 Quarterly Results & Interim Dividend To consider other business matters. Interim Dividend of Rs. 2 per equity share.
2024-05-16 Audited Results
2024-04-23 Bonus issue & Interim Dividend
2024-04-22 Interim Dividend
Date Purpose Remarks
2024-11-20 INTERIM Rs.0.00 Dividend for the FY 2024-25 of 10% i.e. Re. 1.00 per equity share of face value of Rs. 10.00 each.
2024-05-02 INTERIM Rs.0.00 2nd interim dividend of Rs. 4.00/- (Rupees Four only) per equity share having face value of Rs. 10/- each for the financial year 2023-24.
2023-10-28 INTERIM Rs.0.00 Interim Dividend of Rs. 2 per equity share.
View More
Date Purpose Remarks
2025-07-04 Bonus Rs.0.00 issue of equity shares in the ratio of 1:1 of Rs. 10/-.
2024-06-06 Bonus Rs.0.00 issue in the ratio of 3:1 of Rs. 10/-.

Remus Pharmaceuticals F&O

Remus Pharmaceuticals Shareholding Pattern

70.85%
5.03%
18.89%
5.23%

About Remus Pharmaceuticals

  • NSE Symbol
  • REMUS
  • BSE Symbol
  • Managing Director
  • Mr. Arpit Deepakkumar Shah
  • ISIN
  • INE0O5T01011

Similar Stocks to Remus Pharmaceuticals

Remus Pharmaceuticals FAQs

Remus Pharmaceuticals share price is ₹930 As on 13 July, 2025 | 04:27

The Market Cap of Remus Pharmaceuticals is ₹1096.7 Cr As on 13 July, 2025 | 04:27

The P/E ratio of Remus Pharmaceuticals is 37.7 As on 13 July, 2025 | 04:27

The PB ratio of Remus Pharmaceuticals is 4.3 As on 13 July, 2025 | 04:27

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23